Page 1,547«..1020..1,5461,5471,5481,549..1,5601,570..»

Imaging technique shows molecular machinery at work – Phys.Org

Posted: June 8, 2017 at 9:42 am

June 8, 2017 by Geri Clark The camera-based imaging platform Scott Blanchard and his team developed to track how individual proteins, called G protein-coupled receptors (GPCRs), respond to their environments. Credit: Dr. Daniel Terry/Weill Cornell Medicine

New imaging methods that allow researchers to track the individual protein molecules on the surface of cells have been developed by Weill Cornell Medicine investigators. The results offer unprecedented insight into how cells sense and respond to their environments.

G protein-coupled receptors (GPCRs) are proteins that reside within the cellular membrane and relay signals into the cell to regulate fundamental aspects of human physiology. The signals received through GPCRs include everything from light, which activates the proteins in cells that enable vision, to chemicals such as neurotransmitters that regulate mood, to signals that trigger pain. Nearly half of all clinically used drugs work by targeting distinct GPCRs.

"These proteins are critical to every aspect of human physiology," said co-senior study author Scott Blanchard, professor of physiology and biophysics at Weill Cornell Medicine. "We need to know how GPCRs recognize all of these signals, how they process the signals and how they transmit the information into the cell to invoke a specific action. Only in doing so will we be able to develop new generations of drugs that more accurately target these proteins and thus can help without causing collateral damage."

In a paper published June 7 in Nature, Blanchard and colleagues at Weill Cornell Medicine, Stanford and Columbia Universities describe an important advance in this direction, achieved with the use of an imaging technique called single-molecule Fluorescence Energy Transfer (smFRET) that allowed the researchers to watch individual GPCR molecules as they responded to molecules of adrenaline, a hormone that controls functions including heartbeat, breathing and dilation of blood vessels.

"We knew already that the GPCR molecule physically changes upon binding adrenaline and that this process enables it to bind intracellular proteins," Blanchard said. "What we didn't know much about is how this activation process actually happens. And that's the critical missing information that has limited our understanding of drug efficacy."

To enable them to view this process, Blanchard's team developed new reporter molecules called fluorophores that emit fluorescent light and can be attached to the GPCR to inform on its motions when adrenaline binds. The Blanchard lab also developed a new microscope that can follow these light messages with greater accuracy. The researchers then watched and recorded the movements, using complex computation to learn how the protein responds to its interactions with adrenaline and with another protein in the cell, called heterotrimeric G protein, which senses the response and lets the cell know that the GPCR has been activated by adrenaline.

The result is a high-resolution, high-speed film that reveals the details of the molecular relationships that transmit the adrenaline signal through the GPCR into the cell. This revealed to the research team for the first time a series of reversible steps in the process by which an activated GPCR interacts with its intracellular G protein that have never been seen before. This allowed them to conclude their paper by describing why "Quantitative single-molecule imaging investigations will be crucial in . delineating distinct ligand-dependent GPCR signaling pathways."

"These are important insights that wouldn't be possible without the imaging techniques that increase our understanding of how these molecular machines actually work and how signals are conveyed from the outside to the inside of the cell," said Blanchard, who is on related patents, including a patent licensed to Lumidyne for one of the fluorophores used in the study. Blanchard is a co-founder with equity in Lumidyne, a company that focuses on fluorescence technologies. "Being able to see the inner workings of the GPCRs has enormous implications for drug discovery for everything from pain management to heart disease and cancer. The clinical implications of this technology can reach very far."

Explore further: Cholesterol may help proteins pair up to transmit signals across cell membranes

More information: G. Glenn Gregorio et al. Single-molecule analysis of ligand efficacy in 2ARG-protein activation, Nature (2017). DOI: 10.1038/nature22354

Journal reference: Nature

Provided by: Cornell University

Cholesterol may act as a selective glue that binds proteins into paired structures that enable human cells to respond to outside signals, according to a new study in PLOS Computational Biology.

Researchers at the University of Michigan, Stanford University and biotech company ConfometRx have captured the first cryo-electron microscopy snapshots of a key cellular receptor in action.

Researchers from Charit Universittsmedizin Berlin have been studying two proteins that play a vital role in many bodily processes. The aim of the research was to establish how G-protein-coupled receptors (GPCRs) and ...

(Phys.org)A research team at Weill Cornell Medical College has solved the 3D crystal structure of a member protein in one of the most important classes of human proteinsthe G protein-coupled receptors (GPCRs). These ...

For the first time, scientists from the Florida campus of The Scripps Research Institute (TSRI) have created detailed "fingerprints" of a class of surface receptors that have proven highly useful for drug development.

G protein-coupled receptors (GPCRs) are the largest class of cell surface receptors in our cells, involved in signal transmission across the cell membrane. One of the biggest questions is how a signal recognized at the extracellular ...

(Phys.org)One of the greatest challenges in generating energy from renewable sources is finding a way to store the continuously fluctuating energy being produced. Batteries, supercapacitors, and most other energy-storage ...

New imaging methods that allow researchers to track the individual protein molecules on the surface of cells have been developed by Weill Cornell Medicine investigators. The results offer unprecedented insight into how cells ...

Scientists and engineers from the University of Bath have developed biodegradable cellulose microbeads from a sustainable source that could potentially replace harmful plastic ones that contribute to ocean pollution.

Calcium carbonate, or CaCO3, comprises more than 4% of the earth's crust. Its most common natural forms are chalk, limestone, and marble, produced by the sedimentation of the shells of small fossilized snails, shellfish, ...

Using the principles behind the formation of sandcastles from wet sand, North Carolina State University researchers have achieved 3-D printing of flexible and porous silicone rubber structures through a new technique that ...

A team of chemists in Canada has developed a way to process metals without using toxic solvents and reagents.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

The rest is here:
Imaging technique shows molecular machinery at work - Phys.Org

Posted in Cell Medicine | Comments Off on Imaging technique shows molecular machinery at work – Phys.Org

CBSET Expands Its Preclinical Research Services by Adding GLP-Compliant Cell-Based-Therapies Support Capability – Business Wire (press release)

Posted: June 8, 2017 at 9:42 am

LEXINGTON, Mass.--(BUSINESS WIRE)--CBSET Inc., a non-profit GLP translational research institute that specializes in the advancement of novel therapies, announced today that it has expanded its preclinical cell therapy offerings. CBSET recognizes the importance of preclinical partners capable of supporting the needs of the rapidly advancing cell therapy field by providing technical and regulatory support services in the cell therapy and regenerative medicine sectors.

In vivo assessments include (1) stem cell-derived lines, (2) engineered cell lines, (3) autologous strategies, (4) engineered tissues and tissue products, and (5) combination products.

Scientific progress in the cell therapy and regenerative medicine world has advanced rapidly in the last decade, and the need for experienced preclinical support services with translational experience has never been greater for investigators in these fields, said Michael Naimark, CBSETs Director of Business Development. Novel cell and tissue therapies require expanded technical and regulatory approaches to ensure an appropriate level of project support.

Our status as a 501(c)(3) nonprofit research institute and our long track record of safety assessments and successful regulatory submissions give our collaborations impeccable credibility, Naimark added. Applying this experience to support translational programs in regenerative medicine will allow our partners to focus on the scientific integrity of their technology, rather than the conduct and documentation of their critical preclinical projects.

Prior to establishing the new service, CBSET appointed Michael Naimark as Director of Business Development in October 2016. Most recently, he had been employed by the Neural Stem Cell Institute (NSCI) as project manager overseeing the development of a cell-based therapy for macular degeneration under a 4-year award from the New York Stem Cell Foundation.

Michaels significant hands-on experience in managing complex preclinical studies in a variety of animal models puts him in a unique position to interact on CBSETs behalf with existing and potential new sponsors about study goals and regulatory requirements. His industry experience and knowledge of cell-based and biologics therapies are a valuable addition to the CBSET team, said Peter Markham, CEO.

CBSET will launch its new cell-based therapies service at next weeks ISSCR 2017 Annual Meeting in Boston, June 14-17. Visitors to the CBSET Exhibit Booth (#843) can receive a copy of Cell-Based Therapy and FDA Review: Partnering for Success at Your Pre-IND Meeting, meet Mr. Naimark and learn more about CBSETs multi-disciplinary paradigm for in vivo cell-based therapy assessments.

Expert Biomedical Research Services

CBSET was conceived to enable the advancement of novel therapeutics, devices and techniques through ongoing collaboration with its sponsors in the biomedical research community. CBSET provides a full range of GLP (Good Laboratory Practice) and non-GLP research services to support early target validation, lead optimization, and safety and efficacy testing. Whether a Sponsor is developing a new device, surgical model, or needs support for its drug development programs, CBSET offers a wide array of preclinical resources to meet these needs.

For more information about CBSET, contact Michael Naimark, Director of Business Development: +1-781-541-5627, mnaimark@cbset.org

About CBSET CBSET Inc. 500 Shire Way, Lexington, Mass. is the preclinical research leader in critically important therapeutic fields such as interventional cardiology, renal disease and dialysis, chronic drug-resistant hypertension, womens health, minimally invasive surgery, orthopedics, biological and synthetic tissue repair, drug delivery, bioresorbable devices, and combination medical device and drug-eluting products. Learn more about CBSETs expert biomedical research services or please contact us.

Originally posted here:
CBSET Expands Its Preclinical Research Services by Adding GLP-Compliant Cell-Based-Therapies Support Capability - Business Wire (press release)

Posted in Cell Medicine | Comments Off on CBSET Expands Its Preclinical Research Services by Adding GLP-Compliant Cell-Based-Therapies Support Capability – Business Wire (press release)

CAR T-cell therapy Why it’s too soon to speculate about a ‘cure’ for multiple myeloma – HealthNewsReview.org

Posted: June 8, 2017 at 9:42 am

Kathlyn Stone is an associate editor at HealthNewsReview.org. She tweets as @KatKStone.

An experimental immunotherapy treatment for multiple myeloma from a biotech company in China captured wide attention at the just-concluded American Society of Clinical Oncology (ASCO) meeting.

Weve been following news reports from the meeting closely since it kicked off last Friday:

ASCOs news release on the new treatment, a form of CAR T-cell therapy, noted that the phase 1 results are preliminary and that the small trial was short-term. But then it blew past those cautions by speculating that the treatment could send multiple myeloma into long-term remission and might represent a cure for this incurable disease. The treatment costs werent included, either.

Andrae Vandross, MD, a hematology/oncology fellow at UCLA and a contributor to HealthNewsReview.org, said the news release had some important details, such as a discussion of adverse events, particularlycytokine release syndrome (CRS), which affected many patients.

But overall, I wish more attention was paid to the fact that this small trial was to examine safety and efficacy and that much more needs to be done to make statements regarding clinically meaningful impact on disease, Vandross said.

The shortcomings of the news release can be found repeated in some of the news coverage.

Reuterss story, Chinese cell therapy effective in small multiple myeloma trial didnt explain harms well nor mention costs.

FierceBiotechs article played up the horse race aspect of the pharmaceutical industry where competing companies race to get media and investor attention for their preliminary research, ASCO dark horse Nanjing Legend Biotech shines with promising CAR-T data. But costs didnt make it into the discussion.

Nor was the price tag mentioned in The Scientists piece, CAR T-Cell trials boast promising results.

Deborah Korenstein, MD, an internist at Memorial Sloan-Kettering Cancer Center, who did attend the meeting, found some of the reports on the CAR-T study lacking.

None of these articles mentions cost, though CAR-T therapy is very expensive. They do note that the follow-up is short-term so far, though they also talk about long-term remission (in the case of the Reuters piece) or cure (in the ASCO press release), which at the very least sends a mixed message.

NBC News piece, CAR-T Cancer Approach Has Surprising Success in Multiple Myeloma, reflects some of this mixed messaging.After reporting that the results were impressive and remarkable and that the study brings hope of a possible cure, the NBC story eventually broaches the issues of adverse effects and costs: The treatment is expected to cost $200,000 to $300,000, and whos going to pay for that is a big issue, according to a study author.

What does Korenstein think news organizations and public relations people could do better?

Stick to the evidence at hand, avoid speculating about outcomes that havent been determined, and make sure that potential harms are described as thoroughly as benefits.

Certainly there is no evidence so far to support those claims about longer term outcomes. They say it in a hedgy way but to me they shouldnt be mentioning it at all. They also play down the fact that the huge majority of patients had CRS, even if it was often not severe which is generally defined as requiring hospitalization. Its not clear here what severe means.

Dr. Korenstein disclosed that her spouse consults for Vedanta Biosciences.

Kevin Lomangino is the managing editor of HealthNewsReview.org. He tweets as @KLomangino. You'll be tempted

This week we begin a slow roll-out of a new offer of help to those

Today kicks off the annual meeting of the American Society of Clinical Oncology, the world's

See the rest here:
CAR T-cell therapy Why it's too soon to speculate about a 'cure' for multiple myeloma - HealthNewsReview.org

Posted in Cell Therapy | Comments Off on CAR T-cell therapy Why it’s too soon to speculate about a ‘cure’ for multiple myeloma – HealthNewsReview.org

Novartis touts new T-cell therapy data in race for FDA approval – Reuters

Posted: June 8, 2017 at 9:42 am

ZURICH Novartis on Wednesday touted new data from its T-cell therapy CTL019, saying it is on a par with results of experimental molecules from Kite Pharma and Juno Therapeutics that also target aggressive blood cancers.

Three months after infusion, the overall response rate (ORR)among 51 adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) was 45 percent, Novartis said, with 37 percent complete responses (CR), or no sign of disease.

Novartis aims for $1 billion in annual sales for CTL019, a drug made by taking T cells from a patient, reprogramming them in the lab to fight cancer, and re-infusing them. The field is crowded, with Kite and Juno also hunting for approval for drugs whose per-patient costs could top $500,000.

"When you look across the three competitors' data sets, they're all in a similar range of responses," Novartis drug development chief Vas Narasimhan said in an interview. "What's critical is to see the data sets fully mature... and look at the overall safety profile."

Narasimhan said no deaths were linked to CTL019, though three patients died from disease progression within 30 days of infusion. Seven suffered severe neurological events.

While so-called "CAR-T therapies" from Novartis, Kite and Juno are now last resorts for patients who have failed other treatments, more doctors are growing convinced they have promise. Globally, there are some 183 CAR-T trials underway.

In March, Novartis filed CTL019 with the U.S. Food and Drug Administration for fast-track approval in B-cell acute lymphoblastic leukemia (ALL) in young patients. The FDA has scheduled a July 12 public meeting for that.

Novartis could file for FDA approval in DLBCL, the most common form of non-Hodgkin lymphoma (NHL) in adults, around October, with European filings planned about the same time.

Rival Kite Pharma's experimental drug axi-cel is also under expedited U.S. review against advanced NHL, with additional trials underway in leukaemia patients.

Kite has said 41 percent of NHL patients responded to axi-cel treatment at the six-month cutoff, with 36 percent in complete response.

Though Juno Therapeutics has suffered significant setbacks -- patient deaths forced it to abandon its lead CAR-T molecule this year -- the company released fresh data last week on another drug, JCAR017, against NHL.

Novartis is studying why some patients respond to CTL019 while others' cancers avoid detection.

Additional trials are planned, including with newer CAR-Ts combined with other drugs.

"There's just a lot of science that's yet to be understood," Narasimhan said. "I hope we have better answers next year ... for what's going on in the non-responders."

(Reporting by John Miller, editing by Louise Heavens)

BRUSSELS The European Union's top court barred Germany's Dextro Energy on Thursday from making claims about the health benefits of glucose contained in its products, which include Dextrose tablets.

JOHANNESBURG South Africa said on Thursday it was suspending all trade in birds and chicken products from neighboring Zimbabwe after it reported an outbreak of highly pathogenic H5N8 bird flu at a commercial poultry farm.

Follow this link:
Novartis touts new T-cell therapy data in race for FDA approval - Reuters

Posted in Cell Therapy | Comments Off on Novartis touts new T-cell therapy data in race for FDA approval – Reuters

New approach in T-cell therapy to treat cancer – Medical Xpress

Posted: June 8, 2017 at 9:42 am

June 8, 2017 T cells attack a tumor cell and secrete lytic proteins (red/yellow) in order to destroy it. Credit: Helmholtz Zentrum Mnchen

Scientists have armed immune cells with a new surface molecule. This causes the cells to respond particularly aggressively when they encounter a protein that tumors actually use to camouflage themselves from the immune system. Researchers from the Helmholtz Zentrum Mnchen and various partners introduced the method in Cancer Research.

With numerous different entities and millions of people affected, cancer continues to be one of the most prevalent diseases around the world. Scientists are working to find new treatment possibilities, and have been concentrating on the body's own immune system for some time.

"Because cancer emerges from the body's own cells, it is usually difficult for the immune system to distinguish good cells from bad ones," explains Prof. Dr. Elfriede Nner, head of the Tissue Control of Immunocytes Research Group at the Helmholtz Zentrum Mnchen. "But there are ways to support the immune system in recognizing and combating cancer cells."

Focus on T-cell therapy

One approach is the so-called adoptive T-cell therapy, which involves removing immune cells from the body and genetically arming them. The cells are given new structures on the surface that accurately lead them to the cancer cells.

One limitation in this form of therapy is that the binding between the immune cell and the cancer cell is often somewhat weak. "Although this binding can be artificially strengthened, doing so also increases the risk of unwanted binding to healthy structures in the body," explains study leader Nner. She and her team were therefore searching for a different way to improve the defense provided by the immune cells.

Attack instead of sleep mode

In the current work, the researchers present a new surface molecule which comprises two halves. On the outside, it preferentially binds to the PD-L1 molecule, which tumor cells often form in order to thwart the attacking immune cells. On the inside of the T-cells, however, this binding does not activate a sleep mode (which the natural protein would do), and instead activates the T-cell's killer program, making it especially aggressive. Experimental models showed that T-cells armed in this way proliferate more strongly in the tumors and destroyed more tumor cells.

The next step will be to confirm the findings in clinical studies. "If that step succeeds, the approach would enlarge the arsenal of T-cells suitable for adoptive T-cell therapy," Elfriede Nner states. "This could not only make the treatment more effective but would allow it to be used in more patients in the framework of personalized medicine."

Explore further: Platelets suppress T cell immunity against cancer

More information: Ramona Schlenker et al. Chimeric PD-1:28 receptor upgrades low-avidity T cells and restores effector function of tumor-infiltrating lymphocytes for adoptive cell therapy, Cancer Research (2017). DOI: 10.1158/0008-5472.CAN-16-1922

Blood platelets help disguise cancer from the immune system by suppressing T cells, report scientists at the Medical University of South Carolina (MUSC) in the May 5, 2017 issue of Science Immunology. In extensive preclinical ...

Epstein-Barr virus (EBV) prevents infected cells from being attacked by the immune system. The virus drives production of small molecules, so-called microRNAs, that suppress alarm signals sent out by the infected cell. Scientists ...

Immunotherapy is a new and highly promising form of treatment for cancer. In many patients, however, tumors recur after immunotherapy. In the latest issue of the Journal of Experimental Medicine, the members of a research ...

Researchers of the Cancer Virotherapy Research Group of Bellvitge Biomedicine Research Institute (IDIBELL), led by Dr. Ramon Alemany, have developed an oncolytic virus capable of redirecting the patient's immune system against ...

The Shin Kaneko lab found that reprogramming one type of iNKT cells to iPS cells and then differentiating them back results in reprogrammed iNKT cells (re-iNKT cells) that show properties of another type. The ability to make ...

Adult stem cells from mice converted to antigen-specific T cells -- the immune cells that fight cancer tumor cells -- show promise in cancer immunotherapy and may lead to a simpler, more efficient way to use the body's immune ...

Researchers at ANU are working on a new treatment for an aggressive type of leukemia that outperforms standard chemotherapies.

Scientists have armed immune cells with a new surface molecule. This causes the cells to respond particularly aggressively when they encounter a protein that tumors actually use to camouflage themselves from the immune system. ...

Researchers have found a new way to use immunotherapy, a breakthrough mode of cancer treatment which harnesses the patient's immune system, to treat an aggressive form of breast cancer.

Genetic manipulation of exosomes, virus-sized particles released by all cells, may offer a new therapeutic approach to treating pancreatic cancer, according to a study at The University of Texas MD Anderson Cancer Center.

Patients who receive the standard surgical treatment for melanoma that has spread to one or more key lymph nodes do not live longer, a major new study shows.

An analysis of breast cancer data revealed that many small breast cancers have an excellent prognosis because they are inherently slow growing, according to Yale Cancer Center experts. Often, these cancers will not grow large ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the original post here:
New approach in T-cell therapy to treat cancer - Medical Xpress

Posted in Cell Therapy | Comments Off on New approach in T-cell therapy to treat cancer – Medical Xpress

Bioquark Hopes to Bring Dead Back to Life Using Stem Cell Therapy – India West

Posted: June 8, 2017 at 9:42 am

A Philadelphia-based company along with an Indian orthopedic surgeon has said it will start a new type of stem cell therapy that claims it can bring people back from the dead.

Bioquark, led by chief executive Ira Pastor, said it will begin conducting trials of the therapy later in the year in an undisclosed country in Latin America, according to a New York Post report.

Pastor and Indian orthopedic surgeon Himanshu Bansal had initially hoped to run tests in India in 2016 but the Indian Council of Medical Research pulled the plug on their plans and asked them to take the trials elsewhere, the Post reported.

Most countries officially declare someone dead when there is irreversible loss of brain function. The Bioquark therapy boasts it can reboot the brain.

The company said it will begin testing on humans, with no plans to experiment on animals.

Scientists plan to examine individuals aged between 15 and 65 who have been declared brain dead from a traumatic brain injury, the report noted, citing a published study.

The three-stage process starts with harvesting stem cells from the patients own blood before injecting them back into their body. Next, the patient is given a dose of peptides injected into their spinal cord. The final step is a 15-day course of laser and median nerve stimulation while monitoring the patient with MRI scans.

Bansal practices in New Delhi.

Continue reading here:
Bioquark Hopes to Bring Dead Back to Life Using Stem Cell Therapy - India West

Posted in Cell Therapy | Comments Off on Bioquark Hopes to Bring Dead Back to Life Using Stem Cell Therapy – India West

Health & Wellness: 4 most effective ways to control gestational … – Daily Herald

Posted: June 8, 2017 at 9:41 am

When I was pregnant with my fifth baby, I went into the doctors office and found out that I was at risk for gestational diabetes.

I had been preparing for the big event everything from new clothes to a brand new baby carrier but didnt really think about what I had been eating.

As part of everyones prenatal care, about 24 to 28 weeks into your pregnancy, your physician will perform a simple blood test to evaluate how your body reacts to insulin. For almost 10 percent of expectant moms, those results indicate gestational diabetes.

Gestational diabetes poses health risks for the baby, such as high birth weight, jaundice and breathing problems. It can also put you at risk for serious health problems, like high blood pressure and preeclampsia a potentially fatal condition that damages your kidneys and other organs. But, even if you have gestational diabetes, you can minimize your risk with a good diet and exercise plan.

If you have been diagnosed, here are four proven ways to control the negative effects of gestational diabetes:

Leading an active lifestyle is important for everyone, particularly pregnant women. The good news is that it doesnt require a lot of time to benefit from exercise. A simple 10-minute walk around the block or a relaxing yoga session can also help maintain a healthy weight and relieve stress while keeping GD in check.

Doesnt it seem like comfort foods always taste better when you are pregnant? A glass of milk and a doughnut or two or five really satisfy. But many of those foods we crave are loaded with carbohydrates, and that can spike our blood sugar levels. Instead, focus on fresh fruits and vegetables, and whole grains. For example, tart cherries are a delicious addition to your diet.

Tart cherries have been proven to reduce pain and inflammation, Pam Nisevich Bede, RD., a sports nutrition expert, said, adding that cherries reduce arthritic and joint pain and improve heart health.

To avoid spikes in blood sugar levels, try spreading smaller meals throughout the day. Doctors recommend eating three meals and two to three snacks per day. Eating smaller meals more frequently can help you keep your blood sugar levels stable.

By shifting your diet to include low-glycemic foods, you can better control symptoms of gestational diabetes.

Whether you are pregnant or want to be in the near future, its never too late to change your diet, said Ricardo Rueda, MD, PhD. Make an effort to include foods that dont cause sharp rises in your blood sugar and those that have slowly digestible carbs. Doing so lowers your risk of gestational diabetes and, for your baby, it lowers the risk of future obesity.

Fortunately, its easy to incorporate low-glycemic foods into your diet. There are a variety of fresh fruits and vegetables, whole grain cereals and bread, lean cuts of meat, and nonfat dairy products from which to choose.

Pregnancy really is an opportunity to give you and your baby the best start toward healthy futures. By maintaining healthy blood sugar levels with regular exercise, a sensible, balanced diet consisting of frequent meals throughout the day, and talking regularly with your doctor about occurring symptoms, women can still have a happy and healthy pregnancy even with gestational diabetes.

Amy Osmond Cook, Ph.D., is the executive director of the Association of Skilled Nursing Providers, Publisher of 39forlife.com, and CEO of Osmond Marketing. Follow her at @doctorosmond.

View original post here:
Health & Wellness: 4 most effective ways to control gestational ... - Daily Herald

Posted in Diabetes | Comments Off on Health & Wellness: 4 most effective ways to control gestational … – Daily Herald

Baptist camp helps kids fight diabetes – The Commercial Appeal

Posted: June 8, 2017 at 9:41 am

Camp Day2Day is a free camp for youth diagnosed with diabetes or prediabetes sponsored by Baptist Memorial Health Care and the American Diabetes Association. Jim Weber/The Commercial Appeal

Day camper Blayn Dennington withCamp Day2Day checks his blood sugar at the Kroc Center Tuesday afternoon during a break in activities. Camp Day 2Day is a free camp for youth diagnosed with diabetes or prediabetes sponsored by Baptist Memorial Health Care and the American Diabetes Association.(Photo: Jim Weber/The Commercial Appeal)Buy Photo

Like any kidat summer camp, Russell Johnson enjoys theusual offerings of swimming, badminton and touch football, but what will stick with the 12-year-oldmost from the event he's attendingthis week is alesson about how toshopat the supermarket.

"Don't get junk," says the Germantown Middle School student.

Russell was among 32 kids registered forCamp Day2Day, an event for youngsters diagnosed with diabetes or prediabetes, along with those considered at-risk for the disease because of family history and other factors. It'sput on free of charge at The Kroc Center Memphis by Baptist Memorial Health Care and the American Diabetes Association.

The camp's attendance isup45percent from the 22 on hand last year, a reflection, perhaps, of the growing awareness of the perils of diabetes and its grip on the Memphis area.

The city lies within a"diabetes belt" -- a region covering 644 counties in 15 states -- identified by the federal Centers for Disease Control and Prevention. It's an area where at least11 percent of the adult population has been diagnosed with diabetes, an incurable disease characterized by an excess of glucose in the blood, which can lead to nerve damage, blindness, kidney disease, heart trouble and death.

In Shelby County, more than 82,000 residents had been diagnosed with diabetes in 2013, the most recent year for which figures are available, and some 250 people die from it annually.

Camp Day2Day, which attracted kids aged6 through 16,this year includesabout eight youngsterswithType 1 diabetes, traditionally called juvenile diabetes, in which the pancreas produces little or no insulin. Onecamper, Russell, hasType 2 diabetes, the most common form, which occurs when the body develops insulin resistance and can't use the hormone properly.

Autoplay

Show Thumbnails

Show Captions

Another 5 have been diagnosed with prediabetes, meaning their blood-sugar levels are elevated, but not enough so to be considered diabetic. Most of the remainder were considered at-risk for the disease.

Because Type 2 often stems from obesity or poor eating habits, the camp teaches kids about the importance of a healthful diet and exercise. They learn about portion sizes, counting carbohydrates and, during a field trip to a grocery story, how to choose the right foods.

Russellcan trace his disease largely to family history. His mother had diabetes and died from complications and other factors at age 44, and several other family members have been afflicted.

Russell said he'll benefit most from lessons about how to read nutrition labels and keep his weight in check. Heplans a career in nursing.

"I want to help other people who have diabetes," he said.

Another camper, 12-year-old Andrew Lopez, said the activities such as swimming and footballwill helpprevent his prediabetes from progressing to diabetes.

"Mostof my day I like to spend sitting down reading, watching TV," he said. "Being in this environment helps me be more active."

The camp is modeled on the National Diabetes Prevention Program, which focuses on diet, exercise and behavioral changes. The program, developed by the CDC and implemented by local hospitals and health-care providers, seems to have had an impact locally. Between 2008 and 2013, the number of new cases diagnosed in the county fell nearly 19 percent, from 7,918 to 6,439, according to CDC figures.

Day campers Seraiah Johnson and Mallory Johnson (right) withCamp Day2Day play something akin to basketball at the Kroc Center Tuesday afternoon. Camp Day 2Day is a free camp for youth diagnosed with diabetes or prediabetes sponsored by Baptist Memorial Health Care and the American Diabetes Association.(Photo: Jim Weber/The Commercial Appeal)

Jennifer Reed, diabetes education program manager for the Baptist Medical Group Outpatient Care Center, and Melissa Wilson, community health strategist with the ADA, said they're confident the camp can help the kids either avoid developing full-blown diabetes, or, if they already have the disease,at least manage it so they don't develop the debilitating complications.

"It's a process," Reed said. "We hope they'll walk away with a better understanding."

Reach Tom Charlier atthomas.charlier@commercialappeal.comor 901-529-2572 andon Twitter at @thomasrcharlier.

Read or Share this story: http://memne.ws/2sCPPFe

Read the original here:
Baptist camp helps kids fight diabetes - The Commercial Appeal

Posted in Diabetes | Comments Off on Baptist camp helps kids fight diabetes – The Commercial Appeal

Daylight On Diabetes Drugs: Nevada Bill Would Track Insulin … – Kaiser Health News

Posted: June 8, 2017 at 9:40 am

By Emily Kopp June 7, 2017

We encourage organizations to republish our content, free of charge. We dont require much.

For those who need to know the legal underpinnings of using our content, we make it available under the Creative Commons CC BY 4.0 license. Heres what we ask:

You must credit us as the original publisher, with a hyperlink to our site: Kaiser Health News. If possible, please include the original author(s) and Kaiser Health News in the byline. If youd like to explain more about who we are, please use: a national health policy news service that is part of the nonpartisan Henry J. Kaiser Family Foundation. You may use our logo when linking to or posting materials on your site: Download high-resolution .PNG file

Please preserve the hyperlinks in the story.

Its important to note, not everything on khn.org is our original content or available for republishing. If a story is labeled All Rights Reserved, KHN cannot grant permission to republish that item.

Have questions? Let us know at KHNHelp@kff.org

Patients notched a rare win over the pharmaceutical industry Monday when the Nevada Legislature revived a bill requiring insulin makers to disclose the profits they make on the life-sustaining drug. In a handful of other states, bills addressing drug prices have stalled.

Many of the 1.25 million Americans who live with Type 1 diabetes cheered the legislative effort in Nevada as an important first step in their fight against skyrocketing costs of a drug on which their lives depend. The cost of insulin medications has steadily risen over the past decade by nearly 300 percent.

Prominent patient advocacy groups, like the American Diabetes Association, have maintained stony silence while diabetes patients championed the bill and lobbied the legislature during this debate a silence that patients and experts say stems from financial ties.

Normally all of the patient advocacy groups rally around causes and piggyback on each other in a productive way thats what advocacy groups are good at but that hasnt been the case here, said Thom Scher, chief operating officer of Beyond Type 1, which does not accept donations from the pharmaceutical industry. Beyond Type 1 has not issued a formal opinion on the Nevada bill.

Many of the dozens of U.S. diabetes advocacy organizations, large and small, garner significant portions of their funding from insulin manufacturers. The Nevada bill also requires such organizations operating in-state to disclose all contributions they receive from the pharmaceutical industry to discourage that sort of conflict.

In 2016, two of the big three insulin producers Eli Lilly and Sanofi contributed at least $4.7 million to such national patient advocacy groups as the American Diabetes Association, Diabetes Patient Advocacy Coalition (DPAC), JDRF International and the Diabetes Hands Foundation, according to company disclosures. The third major insulin manufacturer, Novo Nordisk, does not disclose its charitable contributions.

The advocacy groups have taken no position on the Nevada legislation. Generally speaking, their advocacy focuses on pressuring insurers to pay the price of insulin, not protesting price rises.

Local diabetes groups, hardly free from conflicts with the pharmaceutical industry, have also stayed on the sidelines.

The Nevada Diabetes Association for Children and Adults officially issued a neutral opinion.

The Nevada Diabetes Association supports regulations on medications. The problem with SB 265 is that it is not just regulating medication but the industry, said Executive Director Sarah Gleich.

The nonprofit does not list its fiscal sponsors on its website or most recent 990 tax form.

We disclose what we have received, and the IRS does not require that we publicly publish from whom, Gleich said. No one is giving out their invitation list to the party.

Gleich said the Nevada Diabetes Association receives table sponsorships and supplies for camp programs from the pharmaceutical industry but nothing that would make a dent on the budget. Auditing non-monetary donations in order to meet the bills transparency requirement would be burdensome, Gleich said.

Membership dues accounted for only about $6,000 of the groups $320,000 in revenue last year, according to its latest tax form.

The American Diabetes Association which operates a Nevada chapter accepted at least $3.9 million from Eli Lilly and Sanofi last year.

The American Diabetes Association believes that no individual in need of lifesaving medications such as insulin should ever go without due to prohibitive costs, Michelle Kirkwood, its director of strategic communications and media relations, said in a statement. She would not say whether the nonprofit supports the bill.

Former American Diabetes Association president Larry Hausner wrote an op-ed in the Nevada Appeal opposing the legislation. Caring for people with diabetes involves more than what they pay for insulin or another medication, Hausner wrote. As a lifelong patient advocate, I know Nevadans expect more out of their elected officials. Hausner, now the president of a consulting and public affairs firm, serves on the board of directors of Research!America, a nonprofit promoting increased federal funding for public health research, alongside Sanofis president of global research & development, Elias Zerhouni.

The Diabetes Hands Foundation expressed neutrality on the bill. This state priority in Nevada is a good step towards a larger conversation about the costs of chronic care conditions like diabetes, said the foundations director of advocacy, Mandy Jones. But its hard to know the particular outcome of this particular bill in the U.S. market.

JDRF International would not comment. DPAC deferred questions to the National Diabetes Volunteer Leadership Council.

Against the backdrop of silence from these patient advocacy groups, a community of diabetes patients on Twitter elevated the bills profile around the hashtag #insulin4all, created by T1International, a group in the United Kingdom that does not accept pharmaceutical donations.

People feel frustrated. At the federal level, were not being seen because theres so much going on politically, said Erin Gilmer, aColorado advocate with Type 1 diabetes. It might have to be a state-by-state movement.

Sen. Yvanna Cancela, who sponsored the bill, said she believed requiring diabetes advocacy groups to reveal their sources of funding was key to understanding their positions and bringing prices down. I believe there should be transparency across the health care system, Cancela said.

Gov. Brian Sandoval said Monday night that he intends to sign the bill, according to a Nevada Independent reporter. If the governor takes no action, the transparency rules become law. The bill, SB539, incorporates provisions of an earlier bill approved by the legislature but vetoed by Sandoval. Sponsors stripped a controversial provision that would have required insulin manufacturers to warn patients 90 days before raising prices, which stoked concerns about drug stockpiling, the Associated Press reported Monday.

The Nevada bill is definitely a step in the right direction, said Elizabeth Rowley, founder and director of T1International. Almost anything requiring more transparency is incredibly important right now, especially at a time when almost all diabetes patient advocacy groups take funding from drug and device companies.

Laura Marston, an advocate in Washington, D.C., with Type 1 diabetes, said that there is plenty of grass-roots support for legislation on insulin prices but that advocacy organizations are not listening to the right people.

There should be more focus on the one thing we need to survive. Without insulin, I die a horrendous death in 12 to 24 hours, Marston said. No grass-roots support? Theres desperation.

KHNs coverage of prescription drug development, costs and pricing is supported in part by the Laura and John Arnold Foundation.

Kaiser Health News (KHN) is a national health policy news service. It is an editorially independent program of the Henry J. Kaiser Family Foundation.

See more here:
Daylight On Diabetes Drugs: Nevada Bill Would Track Insulin ... - Kaiser Health News

Posted in Diabetes | Comments Off on Daylight On Diabetes Drugs: Nevada Bill Would Track Insulin … – Kaiser Health News

Amarillo group fills gap left by juvenile diabetes foundation’s closure … – Amarillo.com

Posted: June 8, 2017 at 9:40 am

Courtney Warren arrived at the Amarillo offices of the Juvenile Diabetes Research Foundation two years ago with her sister and 3-year-old nephew, Bray Jones, who had been diagnosed with Type 1 diabetes after a test revealed his blood sugar was six times the normal amount.

Warren remembers how her family struggled to understand Brays diagnosis, and she said learning to live with a Type 1 child was exhausting for the family.

Warren said the family leaned on JDRF at the time. So, when the foundation closed its West Texas Plains branch in October to redirect funds for more research, Warren joined with a group of concerned parents of children with Type 1 diabetes and past JDRF executive board members to develop a group to help fill the gap.

Now Warren is vice president of Type One Area Diabetics Support, or TOADS, which launched in Amarillo last week under the 501(c)(3) umbrella of the Family Care Foundation. One of the new organizations primary goals is to make sure families are supported.

You dont sleep at night, Warren said of having a young family member with Type 1 diabetes.

You have to test your kid every two hours to test their blood sugar, and theres a thing called dead in bed where they have really low blood sugar and then they just basically fall into a coma and pass away.

Its horrible and really scary, she said

TOADS five-goal plan is to provide support, education, Continuous Glucose Monitoring device drives, tactical kits for hospital visits and scholarships for diabetes camps and eventually college.

Warren said she met with a family last week whose son was recently diagnosed with Type 1 diabetes.

Just the fact that they were there, they were scared and we met them that alone is worth it, Warren said. They have someone they can lean on and have a group they can go to.

Warren said she also wants to go into schools and educate children about why they shouldnt see shame in a Type 1 diagnosis.

TOADS is planning its first large fundraiser this fall, Warren said, and theyre hoping to raise $100,000 for local support.

We just want to help the Type 1s and their families because its a scary diagnosis, Warren said.

We dont have a cure yet, and JDRF is the leading research (group) in the world. ... I do believe they will find a cure within my nephews lifetime, but we just want to help people in the meantime.

Until theres a cure, we are here to help you understand it, help you get the device you need and information and education you need.

What is TOADS?

Type One Area Diabetics Support, or TOADS, is a new organization formed to fill the gap left when the West Texas Plains branch of the Juvenile Diabetes Research Foundation closed its doors in October. TOADS offers support, education, device drives, tactical kits and scholarships to type 1 individuals and their families. For more information, visit their Facebook page facebook.com/fcftoads or call 806-567-8005.

Read the rest here:
Amarillo group fills gap left by juvenile diabetes foundation's closure ... - Amarillo.com

Posted in Diabetes | Comments Off on Amarillo group fills gap left by juvenile diabetes foundation’s closure … – Amarillo.com

Page 1,547«..1020..1,5461,5471,5481,549..1,5601,570..»